Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
40.89 USD | -0.80% | -4.65% | -14.76% |
05-03 | Wedbush Adjusts Ultragenyx Pharmaceutical's Price Target to $47 From $48, Keeps Neutral Rating | MT |
05-02 | Transcript : Ultragenyx Pharmaceutical Inc., Q1 2024 Earnings Call, May 02, 2024 |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.76% | 3.42B | |
+3.84% | 108B | |
+11.20% | 104B | |
+1.28% | 22.33B | |
-13.09% | 22.19B | |
-7.05% | 18.69B | |
-38.36% | 17.74B | |
-10.06% | 17.64B | |
+3.68% | 14.05B | |
+36.73% | 12.51B |
- Stock Market
- Equities
- RARE Stock
- News Ultragenyx Pharmaceutical Inc.
- Transcript : Ultragenyx Pharmaceutical Inc., Q4 2023 Earnings Call, Feb 15, 2024